Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer

TA214 Breast cancer - bevacizumab (in combination with a taxane): review decision - September 2013 information

TA214 Breast cancer - bevacizumab (in combination with a taxane): GE decision paper September 2013 (PDF 107 KB)

TA214 Breast cancer - bevacizumab (in combination with a taxane): review proposal - July 2013 information

TA214 Breast cancer - bevacizumab (in combination with a taxane): Appendix A provisional matrix of stakeholders (PDF 98 KB)

TA214 Breast cancer - bevacizumab (in combination with a taxane): Appendix B proposal paper presented to the Institute's Guidance Executive (PDF 230 KB)

Breast cancer - bevacizumab (in combination with a taxane): Equality impact assessment (PDF 74 KB)

Breast cancer - bevacizumab (in combination with a taxane): final appraisal determination  information

Breast cancer - bevacizumab (in combination with a taxane): final appraisal determination (PDF 306 KB)

Breast cancer - bevacizumab (in combination with a taxane): response to consultee, commentator and public comments on the ACD and comments from website consultation (PDF 186 KB)

Breast cancer - bevacizumab (in combination with a taxane): consultee and commentator comments on the ACD

Breast cancer - bevacizumab (in combination with a taxane): Roche Products (PDF 2.98 MB)

Breast cancer - bevacizumab (in combination with a taxane): Breakthrough Breast Cancer (PDF 130 KB)

Breast cancer - bevacizumab (in combination with a taxane): Department of Health (PDF 4.2 KB)

Breast cancer - bevacizumab (in combination with a taxane): Royal College of Nursing (PDF 58 KB)

Breast cancer - bevacizumab (in combination with a taxane): Royal College of Pathologists (PDF 33 KB)

Breast cancer - bevacizumab (in combination with a taxane): Kensington and Chelsea PCT (PDF 69 KB)

Breast cancer - bevacizumab (in combination with a taxane): Bristol Myers - Squib Pharmaceuticals (PDF 156 KB)

Breast cancer - bevacizumab (in combination with a taxane): Roche Products - new submission (PDF 870 KB)

Breast cancer - bevacizumab (in combination with a taxane): York ERG addendum (PDF 237 KB)

Breast cancer - bevacizumab (in combination with a taxane): appraisal consultation

Breast cancer - bevacizumab (in combination with a taxane): appraisal consultation document information

Breast cancer - bevacizumab (in combination with a taxane): evaluation report

Breast cancer - bevacizumab (in combination with a taxane): pre-meeting briefing (PDF 359 KB)

Breast cancer - bevacizumab (in combination with a taxane): evidence review group report (PDF 1.4 MB)

Breast cancer - bevacizumab (in combination with a taxane): evidence review group report - factual accuracy check (PDF 98 KB)

Breast cancer - bevacizumab (in combination with a taxane): non-manufacturer submissions

Breast cancer - bevacizumab (in combination with a taxane): Breakthrough Breast Cancer (PDF 123 KB)

Breast cancer - bevacizumab (in combination with a taxane): Breast Cancer Care (PDF 65 KB)

Breast cancer - bevacizumab (in combination with a taxane): Royal College of Nursing (PDF 3.5 KB)

Breast cancer - bevacizumab (in combination with a taxane): Royal College of Physicians (NCRI Breast Clinical Studies Group/RCP/RCR/ACP/JCCO) (PDF 69 KB)

Breast cancer - bevacizumab (in combination with a taxane): NHS Kensington and Chelsea (PDF 55 KB)

Breast cancer - bevacizumab (in combination with a taxane): NHS Milton Keynes (PDF 73 KB)

Breast cancer - bevacizumab (in combination with a taxane): manufacturer submissions

Breast cancer - bevacizumab (in combination with a taxane): response from manufacturer 1 (PDF 1.48 MB)

Breast cancer - bevacizumab (in combination with a taxane): response from manufacturer 2 (PDF 85 KB)

Breast cancer - bevacizumab (in combination with a taxane): NICE letter 1 (PDF 137 KB)

Breast cancer - bevacizumab (in combination with a taxane): NICE letter 2 (PDF 112 KB)

Breast cancer - bevacizumab (in combination with a taxane): Roche products (PDF 2.98 MB)

Breast cancer - bevacizumab (in combination with a taxane): expert written personal statements

Breast cancer - bevacizumab (in combination with a taxane): Ellis (PDF 17 KB)

Breast cancer - bevacizumab (in combination with a taxane): Leadbeater (PDF 19 KB)

Breast cancer - bevacizumab (in combination with a taxane): Sinclair (PDF 27 KB)

Breast cancer - bevacizumab (in combination with a taxane): final scope (PDF 27 KB)

Breast cancer - bevacizumab (in combination with a taxane): final matrix (PDF 33 KB)

Breast cancer - bevacizumab (in combination with a taxane): Institute's response to comments on the draft scope (PDF 69 KB)

Breast cancer - bevacizumab (in combination with a taxane): Institute's response to comments on the draft matrix (PDF 26 KB)